The International Coordinating Group on Vaccine Provision approved the release after the government requested doses from the global Ebola stockpile. WHO said 20,000 doses will support a Phase 3 clinical trial focused on Bundibugyo virus disease. The other 50,000 doses will go to frontline and health workers under current vaccination recommendations. WHO and Africa CDC welcomed the allocation, which officials announced on Aug. 20.

WHO incident manager Thierno Baldé said the three-month timeline depends on securing the resources required for the response. The agency has received about $69.3 million of the $115 million it says it needs, or roughly 60%. Teams added more than 400 treatment beds during the past two weeks. They also deployed 100 additional epidemiologists and more than 500 community health workers for surveillance and contact tracing. The response requires vehicles, ambulances, medical supplies and personnel across a growing affected area.

The Democratic Republic of the Congo recorded 26,064,143 malaria cases in 2025. The country also reported 29,938 deaths linked to the disease during the year. Guy Esebe Dembo, deputy director of the National Malaria Control Programme, announced the figures during a campaign launch in Ituri province. Dembo said malaria remains the country’s main public health challenge. The new totals confirm a heavy disease burden across one of Africa’s most malaria-affected countries.

DR Congo’s Ebola outbreak has killed 1,916 people and produced 4,209 confirmed cases, according to official data through Aug. 7. Ituri remains the center of the epidemic, with 3,636 confirmed cases and 1,551 deaths. Health authorities also counted 595 patients receiving care in isolation. Another 828 people have recovered from the Bundibugyo virus disease outbreak.

The statistical findings also show that high BMI resulted in over 150,000 lost years of life across all demographic groups in a single year. The comprehensive epidemiological investigation examined underlying causes of death to determine how elevated body mass index contributes to chronic health conditions. Research findings identified cardiovascular complications as the primary contributor to mortality, with coronary heart diseases accounting for 2,009 deaths. Demographic breakdowns within the dataset demonstrate that mortality risks associated with elevated weight expand significantly alongside advancing age.

Moderna has started a Phase 1 trial of an experimental vaccine against Bundibugyo ebolavirus in Canada. The first participant received the mRNA-1469 vaccine on August 3 at a site in Truro, Nova Scotia. The trial comes as the virus continues spreading across several provinces in the Democratic Republic of the Congo. The World Health Organization has classified the outbreak as a public health emergency of international concern.